Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)
Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation with one or more risk factor for stroke or systemic embolism
NICE recommends apixaban as a possible treatment to prevent stroke and systemic embolism in some people with atrial fibrillation without underlying heart valve disease (see below).
Who can have apixaban ?
You should be able to have apixaban if 1 or more of the following apply:
- you have had a stroke or transient ischaemic attack (mini stroke) in the past
- you are 75 or older
- you have high blood pressure
- you have diabetes
- you have heart failure with symptoms.
Why has NICE said this ?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended apixaban as a treatment option because it works as well as other treatments available on the NHS. Although it also costs more than some other treatments, this was justified by the benefits it provided.
- TA275 Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: guidance (web format)
This page was last updated: 10 March 2014
- Web format
- Full Guidance (PDF)
- TA275 Apixaban ar gyfer atal str˘c ac emboledd mewn pobl Ô ffibriliad atr´aidd- Gwybodaeth i'r cyhoedd (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.